Evidence map›Paper›PMID 40146227›Full record

ArticleThe Journal of clinical investigation2025

Prefrontal correlates of fear generalization during endocannabinoid depletion.

Luis E Rosas-Vidal, Saptarnab Naskar, Leah M Mayo, Irene Perini, Rameen Masroor, Megan Altemus, Liorimar Ramos-Medina, S Danyal Zaidi, Hilda Engelbrektsson, Puja Jagasia and 2 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Luis E Rosas-VidalStephen M. Stahl Center for Psychiatric Neuroscience, Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Saptarnab NaskarStephen M. Stahl Center for Psychiatric Neuroscience, Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Leah M MayoHotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Irene PeriniLinköping University, Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping, Sweden.
Rameen MasroorStephen M. Stahl Center for Psychiatric Neuroscience, Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Megan AltemusVanderbilt University Medical Center, Department of Psychiatry and Behavioral Sciences, Nashville, Tennessee, USA.
Liorimar Ramos-MedinaStephen M. Stahl Center for Psychiatric Neuroscience, Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
S Danyal ZaidiStephen M. Stahl Center for Psychiatric Neuroscience, Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Hilda EngelbrektssonLinköping University, Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping, Sweden.
Puja JagasiaVanderbilt University Medical Center, Department of Psychiatry and Behavioral Sciences, Nashville, Tennessee, USA.
Markus HeiligLinköping University, Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linköping, Sweden.
Sachin PatelStephen M. Stahl Center for Psychiatric Neuroscience, Department of Psychiatry and Behavioral Sciences, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.

Funding

2-Arachidonoylglycerol signaling in anxiety, depression, and stress adaptationR01MH107435 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PATEL, SACHIN · 2016 to 2025
$5.0M
Opioid-BNST interactions in the regulation of trauma-induced anxiety statesK08MH126166 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROSAS-VIDAL, LUIS EDUARDO · 2021 to 2024
$728k
NIMH NIH HHS K08 MH126166NIMH NIH HHS L70 MH134387NIMH NIH HHS R01 MH107435
6 · The paper itself

Abstract

Maladaptive fear generalization is one of the hallmarks of trauma-related disorders. The endocannabinoid 2-arachidonoylglycerol (2-AG) is crucial for modulating anxiety, fear, and stress adaptation, but its role in balancing fear discrimination versus generalization is not known. To address this, we used a combination of plasma endocannabinoid measurement and neuroimaging in a childhood maltreatment-exposed and -nonexposed mixed population, combined with human and rodent fear-conditioning models. Here we show that 2-AG levels were inversely associated with fear generalization at the behavioral level in both mice and humans. In mice, 2-AG depletion increased the proportion of neurons that respond to, and the similarity of neuronal representations for, both threat-predictive and neutral stimuli within prelimbic prefrontal cortex neuronal ensembles. In humans, increased dorsolateral prefrontal cortical-amygdala resting-state connectivity was inversely correlated with fear generalization. These data provide convergent cross-species evidence that 2-AG is a key regulator of fear generalization and further support the notion that 2-AG deficiency could represent a trauma-related disorder-susceptibility endophenotype.

Indexed as

Arachidonic AcidsEndocannabinoidsFearGeneralization, PsychologicalGlyceridesPrefrontal CortexAdultAmygdalaAnimalsFemaleHumansMaleMiceArachidonic AcidsEndocannabinoidsGlyceridesglyceryl 2-arachidonateBehaviorClinical ResearchNeuroimagingNeurosciencePsychiatric diseases

Identifiers

PMID40146227
PMCPMC12126220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.